Mark Wilkinson

Mark completed his undergraduate and masters in Biochemistry at the University of Oxford. He then completed an MSc and PhD at Imperial College London, where he developed a biosynthetic platform for antimalarial drug discovery and a single molecule method for studying protein folding. Before joining Bactobio, he was based at the Drug Discovery Unit at GlaxoSmithKline in Madrid.

Mark joined Bactobio in September 2020 and oversees the scientific projects from bacterial generation thorough to compound discovery.